Chapter 7

References

REFERENCES

(201)

Abdalla DS, Campa A, Monteiro HP. Low density lipoprotein oxidation by

stimulated neutrophils and ferritin. Atherosclerosis. 1992;97:149-59.

Alderman MH, Uric acid and cardiovascular risk. Curropin Pharmacology.

2002; 2:126-30.

al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV.

Serum non-transferrin-bound iron in beta-thalassaemia major patients treated

with desferrioxamine and L1. Brit J Haematol. 1992;82:431-6.

Anderson GJ. Non-transferrin-bound iron and cellular toxicity. J Gastroenterol

Hepatol. 1999;14(2):105-8.

Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM and Pennell DJ.

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine

on myocardial iron concentrations and ventricular function in beta-

thalassaemia. The Lancet. 2002;360 (9332); 516-20.

Andrewsa NC. Disorders of iron metabolism. N Engl J Med. 1999;341:1986-

95.

Andrews NC. The iron transporter DMT 1. Int J Biochem Cell Biol.

1999;31:991-4.

Andrews, NC. Iron homeostasis: insights from genetics and animal models.

Nat. Rev., Genet. 2000;1:208-17.

Ann Chen Wu, Leann Lesperance, Henry Bernstein. Screening for iron

deficiency, Pediatrics in Review. May 2002;23(5):171-8.

Aruoma OI, Bomford A, Polson RJ, Halliwell B. Nontransferrin-bound iron in

plasma from hemochromatosis patients: Effect of phlebotomy therapy. Blood.

1988;72:1416-9.

Ascherio A, Willett WC, Rimm EB, Giovannucci EL, Stampfer MJ: Dietary

iron intake and risk of coronary disease among men. Circulation. 1994;89:969-

74.

Bacon BR, Britton RS. The pathology of hepatic iron overload: a free

radical—mediated process? Hepatology. 1990; 11: 127-37.

Baer DM, Tekawa IS, Hurley LB: Iron stores are not associated with acute

myocardial infarction. Circulation. 1994;89:2915-8.

Bagdade J, Casaretto A, Albers J. Effects of chronic uremia, hemodialysis and

renal transplantation on plasma lipids and lipoproteins in man. J Lab Clin Med

1976; 87:37-48.

REFERENCES

(202)

Balla G, Jacob HS, Eaton JW, Belcher JD, Vercellotti GM. Hemin: a possible

physiological mediator of low density lipoprotein oxidation and endothelial

injury. Arterioscler Thromb. 1991;11:1700-11.

Batey RG, Lai Chung Fong P, Shamir S, Sherlock S. A non-transferrin-bound

serum iron in idiopathic hemochromatosis. Dig Dis Sci. 1980;25:340-6.

Baykan M, Celik U, Orem A, Malkoc M, Erdol C, Baykan EC, Orem C,

Karahan B: Iron status and its relationship with lipid peroxidation in patients

with acute myocardial infarction. Acta Cardiol. 2001;56:277-281.

Baylor, College of Medicine, Lipids Online, 2001. Heterogeneity of HDL.

Retrieved on February 2006.

Beaumont C, Beris P, Beuzard Y, Brugnara C, eds. Disorders of Iron

Homeostasis, Erythrocytes, Erythropoiesis. Paris: European School of

Haematology, 2006:409e19.

Beinert H, Holm RH, Mqnck E. Iron-sulfur clusters: nature‟smodular,

multipurpose structures. Science. 1997; 277:653-59.

Beutler E. History of iron in medicine. Blood Cells Mol Dis. 2002, Nov-

Dec;29(3):297-308.

Biemond P, Van Eijk HG, Swaak AJG, Koster JF. Iron mobilization from

ferritin by superoxide derived from stimulated polymorphonuclear leukocytes:

possible mechanism in inflammatory diseases. J Clin Invest. 1984;73:1576-9.

Blessing OI, Oloruntoba F, Olarewaju MO. Plasma Glucose, Creatinine and

Urea levels in Type 2 Diabetic patients attending A Nigerian teaching hospital.

Research Journal of Medical Sciences. 2011;5(1):1-3.

Bonkovsky HL, Lambrecht RW, Shan Y. Iron as a co-morbid factor in

nonhemochromatotic liver disease. Alcohol. 2003;30:137-44.

Bonkovsky HL. Iron and the liver. 1991; Am J Med Sci 301: 32-43.

Bonsdorff VL, Lindeberg E, Sahlstedt L, Lehto J, Parkkinen J. Bleomycin -

detectable iron assay for nontransferrin bound iron in hematologic

malignancies. Clin Chem 2002;48:307-14.

Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del

Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R,Piga A,

Cnaan A: Survival and complications in patients with thalassemia major

treated with transfusion and deferoxamine. Haematologica. 2004, 89:1187-93.

REFERENCES

(203)

Bradley SJ, Gosriwatana I, Srichairatanakool S, Hider RC, Porter JB. Non-

transferrin-bound iron induced by myeloablative chemjournalapy. Br J

Haematol. 1997;99:337-43.

Brady HR, Singer GG, Acute renal failure. Lancet. 1995; 346:1533-40.

Brazzolotto X, Gaillard J, Pantopoulos K, Hentze MW, Moulis JM. Human

cytoplasmic aconitase (iron regulatory protein 1) is converted into its [3Fe-4S]

form by hydrogen peroxide in vitro but is not activated for iron-responsive

element binding. J Biol Chem.1999;274:21625-30.

Breuer W, Cabantchik ZI. A fluorescence-based one step assay for serum non-

transferrin bound iron (NTBI). Anal Biochem. , 2001;299:194-202.

Breuera W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI.

Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound

iron used for assessing chelation therapy. Blood. 2001;97:792-8.

Breuerb W, Hershko C, Cabantchik ZI. The importance of non-transferrin

bound iron in disorders of iron metabolism. Transfus Sci. 2000;23:185-92.

Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI. The

assessment of serum nontransferrin-bound iron in chelation therapy and iron

supplementation. Blood. 2000;95:2975-82.

Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH,

Subramaniam VN, Powell LW, Anderson GJ, Ramm GA. Disrupted hepcidin

regulation in HFE-associated haemochromatosis and the liver as a regulator of

body iron homoeostasis. Lancet. 2003 Feb 22;361(9358):669-73.

Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine

in preventing complications of iron overload in patients with thalassemia

major. N Engl J Med 1994;331:567-73.

Bruick, RK. Oxygen sensing in the hypoxic response pathway: regulation of

the hypoxia-inducible transcription factor. Genes Dev. 2003;17, 2614- 23.

Buja LM, Roberts WC. Iron and the heart. Am J Med. 1971;51:209-21.

Burkitt MJ, Milne L, Raafat A. A simple, highly sensitive and improved

method for the measurement of bleomycin-detectable iron: the „catalytic iron

index‟ and its value in the assessment of iron status in haemochromatosis. Clin

Sci. 2001;100:239-47.

Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI labile plasma iron in

iron overload. Best Pract Res Clin Haematol. 2005;18:277-87.

REFERENCES

(204)

Carlson LA, Regnström J. Increase of electrophoretic mobility and of content

of soluble proteins of human plasma beta-lipoproteins by incubation of plasma

in vitro. Atherosclerosis. 1984 Dec;53(3):309-19.

Carmine TC, Evans P, Bruchelt G, Evans R, Handretinger R, Niethammer D,

et al. Presence of iron catalytic for free radical reactions in patients undergoing

chemjournalapy: implications for therapeutic management. Cancer Lett.

1995;94:219-26.

Caroline Le Lan, Olivier Loréal, Tally Cohen, Martine Ropert, Hava

Glickstein, Fabrice Lainé, Michel Pouchard, Yves Deugnier, André Le Treut,

William Breuer, Z. Ioav Cabantchik and Pierre Brissot. Redox active plasma

iron in 82Y/C282Yhemochromatosis. Blood. 2005; 105: 4527-31

Cazzola M, Huebers HA, Sayers MH, MacPhail AP, Eng M, Finch CA.

Transferrin saturation, plasma iron turnover, and transferrin uptake in normal

humans. Blood. 1985;66:935-9.

Cerriotti, F. and Cerriotti, G. Improved direct specific determination of serum

iron and total iron-binding capacity. Clin. Chem. 1980; 26, 327-31.

Chan MK, Varghese Z, Moorhead JF. Lipid abnormalities in uremia, dialysis,

and transplantation. Kidney Int. 1981 May;19(5):625-37.

Chatterjea MN and Shinde R. Text book of Medical Biochemistry. 6th

ed.

Jaypee brothers,New Delhi; 2005.

Chau L. Iron and atherosclerosis. Proceedings of the National Science

Council, Republic of China - Part B. Life Sci. 2000;24:151-5.

Clellan WM, knight DF, Karp H, Brown ww, Early detection and treatment of

renal disease in hospitalized diabetic and hypertensive patients: important

difference between practice and published guidelines. Am J Kidney Dis. 1997;

29:368 -75.

Collins KE, Collins CH, Bertran CA, Dolan J. Stainless steel surfaces in LC

systems, Part 1-corrosion and erosion. LC GC Int. 2000;13:464-70.

Cortelezzi A, Cattaneo C, Cristiani S, Duca L, Sarina B, Deliliers GL, et al.

Non-transferrin-bound iron in myelodysplastic syndromes: a marker of

ineffective erythropoiesis? Hematol J. 2000;1:153-8.

Corti MC, Guralnik JM, Salive ME, Ferrucci L, Pahor M, Wallace RB, et al.

Serum iron level, coronary artery disease, and all-cause mortality in older men

and women. Am J Cardiol. 1997;79:120-7.

Cunninghama MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of b-

thalassemia major in North America. Blood 2004; 104:34-9.

REFERENCES

(205)

Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR; Thalassemia Clinical

Research Network. Blood. 2004 Jul 1;104(1):34-9.

Cuzzocrea S, Zingarelli B, Costantino G, Szabo A, Salzman AL, Caputi AP, et

al. Beneficial effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose)

synthetase in a rat model of splanchnic artery occlusion and reperfusion. Br J

Pharmacol. 1997;121:1065-74.

Dandona P, Hussain MA, Varghese Z, Politis D, Flynn DM, Hoffbrand AV.

Insulin resistance and iron overload. Ann Clin Biochem. 1983;20:77-9.

Danesh J, Appleby P. Coronary heart disease and iron status: meta-analyses of

prospective studies. Circulation. 1999;99:852-4.

Daniel HC, Andrew JK, Sam JL, Hilary ER, The Washington manual of

medical therapeutics. 2007. Medical -780 -1.

Daphne L. van der A, Joannes JM Marx, Diederick E. Grobbee, Marjolein H.

Kamphuis, Niki A. Georgiou, J. Henny van Kats-Renaud, William Breuer, Z.

Ioav Cabantchik, Mark Roest, Hieronymus A.M. Voorbij, Yvonne T. van der

Schouw. Non-Transferrin Bound Iron and Risk of Coronary Heart Disease in

Postmenopausal women. Journal of the American Heart association, (2006);

113: 1942-9.

Daugirdas JT, Blake PG, and Ing TS. Lippincott Williams and Wilkins,

Handbook of dialysis (3rd

Edition); Philadelphia. 2001.

Davies DF, Shock NW. Age changes in glomerular filtration rate, effective

renal plasma flow and tubular excretory capacity in adult males. J Clin

Invest. 1950;29:496-504.

De Feo TM, Fargion S, Duca L, Cesana BM, Boncinelli L, Lozza P, et al.

Non-transferrin-bound iron in alcohol abusers. Alcohol Clin Exp Res.

2001;25:1494-9.

de Valk B, Addicks MA, Gosriwatana I, Lu S, Hider RC, Marx JJ. Non-

transferrin-bound iron is present in serum of hereditary haemochromatosis

heterozygotes. Eur J Clin Invest. 2000 Mar;30(3): 248-51.

Derman DP, Green A, Bothwell TH, Graham B, McNamara L, MacPhail AP,

Baynes RD.A systematic evaluation of bathophenanthroline, ferrozine and

ferene in an ICSH-based method for the measurement of serum iron. Ann Clin

Biochem. 1989 Mar;26 ( Pt 2):144-7.

Derstine JL, Murray-Kolb LE, Yu-Poth S, Hargrove RL, Kris-Etherton PM,

Beard JL: Iron status in association with cardiovascular disease risk in 3

controlled feeding studies. Am J Clin Nutr. 2003;77:56-62.

REFERENCES

(206)

Descamps LB, Witko SV, Nguyen KT, Nguyen AT, Gausson V, Mothu V, et

al. Early prediction of IgA nephropathy progression: Proteinuria and AOPP

are strong prognostic markers. Kidney Int. 2004;66:1606-12.

Detivaud L, Nemeth E, Boudjema K, Turlin B, Troadec MB, Leroyer P, et al.

Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin

levels, and hepatic function. Blood. 2005;106: 746-8.

Devlin RJ, Henry JA. "Clinical review: Major consequences of illicit drug

consumption". CritCare.2008; 12 (1):202. doi:10.1186/cc6166. PMC 2374627.

Dierk H. Endemann and Ernesto L. Schiffrin Mechanisms of Hypertension:

Cells, Hormones, and the Kidney:Endothelial Dysfunction,

JASN.2004;15:1983-92.

Dimeski G, Jones BW. Lipaemic samples: effective process for lipid reduction

using high speed centrifugation compared with ultracentrifugation. Biochem

Med (Zagreb). 2011;21(1):86-92.

Dürken M, Nielsen P, Knobel S, Finckh B, Herrnring C, Dresow B, et al. Non-

transferrin-bound iron in serum of patients receiving bone marrow transplants.

Free Rad Biol Med. 1997;22:1159-63.

Emerit J, Beaumont C, Trivin F. Iron metabolism, free radicals, and oxidative

injury. Biomed Pharmacother. 2001 Jul;55(6):333-9. Review.

Erhardt L, Herlitz J, Bossaert L, et al. (2002). "Task force on the management

of chest pain" .Eur.Heart,J. 23 (15):1153-76. doi:10.1053/euhj.2002.3194.

Erhardt LR, Sjogren A, Sawe U. Late rise in SGPT after Acute Myocardial

infarction. Acta Medica Scandinavica. 1974;196:47-51.

Eskelinen S, Haikonen M, Räisänen S. Ferene-S as the chromogen for serum

iron determinations. Scand J Clin Lab Invest. 1983 Sep;43(5):453-5.

Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik

ZI. Labile plasma iron in iron overload: redox activity and susceptibility to

chelation. Blood. 2003 Oct 1;102(7):2670-7.

Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron

formulations and its potential for generating plasma nontransferrin-bound iron

in dialysis patients. Eur J Clin Invest. 2002;32:42-49.

European Society of Cardiology (ESC) Committee for Practice Guidelines

(CPG). European guidelines on cardiovascular disease prevention in clinical

practice: executive summary: Fourth Joint Task Force of the European Society

of Cardiology and Other Societies on Cardiovascular Disease Prevention in

REFERENCES

(207)

Clinical Practice (Constituted by representatives of nine societies and by

invited experts). Eur Heart J. 2007 Oct;28(19):2375-414.

Evans PJ and Halliwell B. measurement of iron and Copper in biological

systems: Bleomycin and copper-phenanthroline assays, Methods. Enzymol.

1994;233:82-92.

Evans PJ, Evans R, Kovar IZ, Holton AF, Halliwell B. Bleomycin-detectable

iron in the plasma of premature and full-term neonates. FEBS Lett.

1992;303:210-12.

Evans RW, Rafique R, Zarea A, et al. Nature of non-transferrin-bound iron:

Studies on iron citrate complexes and thalassemic sera. J Biol Inorg Chem

2008;13:57-74.

Farnaud S, Evans RW. Lactoferrin--a multifunctional protein with

antimicrobial properties. Mol Immunol. 2003 Nov;40(7):395-405.

Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is

mutated in patients with hereditary haemochromatosis. Nat Genet.

1996;13:399-408.

Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Iron stores, blood donation,

and insulin sensitivity and secretion. Clin Chem. 2005;51:1201-5.

Finch C. Regulators of iron balance in humans. Blood . 1994;84:1697-1702.

Franchini M. Hereditary iron overload: update on pathophysiology, diagnosis,

and treatment. Am J Hematol. 2006;81:202- 9.

Frazer DM, Wilkins SJ, Becker EM, Murphy TL, Vulpe CD, McKie AT,

Anderson GJ. A rapid decrease in the expression of DMT1 and Dcytb but not

Ireg1 or hephaestin explains the mucosal block phenomenon of iron

absorption. Gut. 2003 Mar;52(3):340-6.

Fridovich I. Oxygen toxicity: a radical explanation. J Exp Biol.

1998;201:1203-9.

Friedwald WT, Levy RI, Fredrickson D.S, Estimation of the concentration in

plasma, without use of the preparative ultracentrifuge. Clinical chem. 1972;

18:499-502.

Fytili CI, Progia EG, Panagoutsos SA, Lipoprotein abnormalities in

hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail.

2002;24:623-630.

Gackowski D, Kruszewski M, Jawien A, Ciecierski M, Olinski R. Further

evidence that oxidative stress may be a risk factor responsible for the

development of atherosclerosis. Free Radic Biol Med. 2001;31:542-7.

REFERENCES

(208)

Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010 May

21;5:11.

Galaris D, Mantzaris M, Amorgianiotis C. Oxidative stress and aging: the

potential role of iron. Hormones (Athens). 2008 Apr-Jun;7(2):114-22.

Ganz T. Hepcidin in iron metabolism. Curr Opin Hematol. 2004;11:251-4.

Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia

of inflammation. Blood. 2003;102(3):783-8.

Gardenghi S, Marongiu MF, Ramos P, et al. Ineffective erythropoiesis in b-

thalassemia is characterized by increased iron absorption mediated by down-

regulation of hepcidin and upregulation of ferroportin. Blood. 2007;109:5027-

35.

Genest J Jr, Marcil M, Denis M, and Yu L, High density lipoproteins in health

and in disease. J Investing Med. 1999; 47:31-42.

Gltlin D and Perricelli A, Synthesis of serum albumin, prealbumin. -

Fetoprotein, l- Antitrypsin and transferring by the human yolk sac. Nature.

1970;228:995-997.

Gopalan C, Ramshastri BV, Balasubramanium SC. Nutritive values of Indian

food. Food and their nutrient content; 1995;4:19-78.

Gosriwatana I, Loréal O, Lu S, Brissot P, Porter J, Hider RC. Quantification of

non-transferrin-bound iron in the presence of unsaturated transferrin. Anal

Biochem. 1999;273:212-20.

Goyal A, Mahaffey KW, Garg J, Nicolau JC, Hochman JS, Weaver WD,

Theroux P, Oliveira GB, Todaro TG, Mojcik CF, Armstrong PW, Granger

CB. Prognostic significance of the change in glucose level in the first 24 h

after acute myocardial infarction: results from the cardinal study. Eur Heart J.

2006; 27:1289-97.

Graham G, Bates GW, Rachmilewitz EA, Hershko C. Non-specific serum iron

in thalassaemia: quantitation and chemical reactivity. Am J Hematol.

1979;6:207-17.

Gregory LC. Lipids and lipoproteins. In: Christenson RH, Gregory LC,

Johnson LJ. Appleton and Lange's outline review clinical chemistry. New

York: McGraw Hill. 2001;27-50.

Greenspan's basic & clinical endocrinology, Mc Graw Hill, 9th

ed. 2011.

REFERENCES

(209)

Griffiths JD, Campbell LJ, Woodruff IW, Cruickshank D, Matthews JP, Hunt

D, Campbell DG, Cowling DC: Acute changes in iron metabolism following

myocardial infarction. Am J Clin Path. 1985;84:649-54.

Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non-

transferrin bound iron in plasma or serum from patients with idiopathic

hemochromatosis. J Biol Chem. 1989;264:4417-22.

Gutman RA, Uy A, Shalhoub RJ, Wade AD, Oconnell JMB. and Recant L.

Hypertriglyceridemia in chronic non-nephrotic renal failure. Amer. J. Clinical.

Nutr. 1973;26:165-72.

Gutteridge JMC and Halliwell B. Radical promoting loosely-bound iron in

biological fuids and the bleomycin assay. Life Chem Rep. 1987;4:113-42.

Gutteridge JMC, Rowley DA and Halliwell B. Superoxide-dependent

formation of hydroxyl radicals I in the presence of iron salts. Biochem J.

1981;199:263-5.

Gutteridge JMC, Rowley DA, Griffiths E, Halliwell B. Low-molecular-weight

iron complexes and oxygen radical reactions in idiopatic

haemochromatosis.Clin Sci. 1985;68:463-7.

Gutteridge JMC, Smith A. Antioxidant protection by haemopexin of

haemstimulated lipid peroxidation. Biochem J. 1988;256:861-5.

Gutteridge JMC. Ferrous ions detected in cerebrospinal fuid by using

bleomycin and DNA damage. Clin Sci. 1992;82:315-20.

Gutteridge JMC. Iron promotors of the Fenton reaction and lipid peroxidation

can be released from haemoglobin by peroxides. FEBS Lett. 1986;201:291-5.

Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC. Heart failure in

beta-thalassemia syndromes: a decade of progress. Am J Med 2005;118:957-

67.

Haines TH. "Do sterols reduce proton and sodium leaks through lipid

bilayers” Prog Intern. Med. 2001;148(1):36-69:299-324.

Halliwell B, Aruoma OI, Mufti G, Bomford A. Bleomycindetectable iron in

serum from leukaemic patients before and after chemjournalapy. Therapeutic

implications for treatment with oxidant-generating drugs. FEBS Lett.

1988;241:202-4.

Halliwell B, Gutteridge JMC. Role of free radicals and catalytic metal ions in

human disease: an overview. Methods Enzymol. 1990;186:1-85.

REFERENCES

(210)

Halliwell B. Free radicals and antioxidants: a personal view. Nutr Rev 1994;

52:253-65.

Halliwell B. The role of oxygen radicals in human disease, with particular

reference to the vascular system. Haemostasis. 1993;23(suppl 1):118-26.

Han KE and Okada, S. Serum bleomycin detectable iron in patients with

thalassemia major with normal range of serum iron. Acta Med Okayama.

1995;49:117-21.

Harper HA, Rodwell VW, Mayes PA. Essential trace elements, Review of

Physiological chemistry; 1977;16:531-4.

Harrison D D-Findik E. Klein, C. Crist, J. Evans, N. Timchenko, J. Gollan,

Iron mediated regulation of liver hepcidin expression in rats and mice is

abolished by alcohol, Hepatology 2007; 46:1979-85.

Harrison P, Marwah SS, Hughes RT, Bareford D. Non-transferrin bound iron

and neutropenia after cytotoxic chemotherapy. J Clin Pathol. 1994;47:350-2.

Harrison P, Neilson JR, Marwah SS, Madden L, Bareford D, Milligan D W;

Role of non-transferrin bound iron in iron overload and liver dysfunction in

long term survivors of acute leukaemia and bone marrow transplantation. J

Clin pathol. 1996; 49:853-56.

Harrison-Findik DD, Klein E, Crist C, Evans J, Timchenko N, Gollan J. Iron-

mediated regulation of liver hepcidin expression in rats and mice is abolished

by alcohol. Hepatology. 2007;46:1979-85.

Hershko H, Graham G, Bates GW, Rachmilewitz E. Nonspecific serum iron in

thalassaemia: An abnormal serum iron fraction of potential toxicity. Br J

Haematol. 1978;40:255-63.

Hersko C. Prevalence and causes of iron deficiency anaemia. In: Beaumont C,

Beris P, Beuzard Y, Brugnara C, eds. disorders of Iron Homeostasis,

Erythrocytes, Erythropoiesis. Paris: European School of Haematology,

2006;409-19.

Hider RC. Nature of nontransferrin-bound iron. Eur J Clin Invest 2002;32:50-

4.

Higgs DR, Thein SL, Woods WG. The molecular pathology of the

thalassaemias. In: Weatherall DJ, Clegg B, eds. The thalassaemia syndromes.

4th

ed. Oxford, England: Blackwell Science, 2001;133-91.

Himmelfarb Jonathan MD, DB Morgan, Margaret E carver, RB Payne,

Relationship between serum albumin level before initiating haemodialysis and

REFERENCES

(211)

angiographic severity of coronary atherosclerosis in end-stage renal disease

patients. British Med J. 1977;2:929-32.

Hoffbrand AV. Diagnosing myocardial iron overload. Eur Heart J. 2001

Dec;22(23):2140-1.

Horner MJ, Ries LAG, Krapcho M, Neyman N, et al. (eds).. "SEER Cancer

Statistics Review, 1975-2006". Surveillance Epidemiology and End Results

(SEER). Bethesda, MD: National Cancer Institute. Retrieved November 2009.

Horwitz L, Rosenthal E. Iron-mediated cardiovascular injury. Vasc Med.

1999;4:93-9.

Hussain MK. Serum lipid profile in renal failure patients February 2008,

Essentials of Pathophsiology Concept of Altered Health States Medical.

2006;1184-6.

Ikuta K, Zak O, Aisen P. Recycling, degradation and sensitivity to the

synergistic anion of transferrin in the receptor-independent route of iron

uptake by human hepatoma (HuH-7) cells. Int J Biochem Cell Biol.

2004;36:340-52.

Inamura J, Ikuta K, Jimbo J, et al. Upregulation of hepcidin by interleukin-

1beta in human hepatoma cell lines. Hepatol Res. 2005;33:198-205.

Irshad A, Khan IU, Baloch MK and Mustafa G. Comparative Lipid profile

studies in Cardiac and Diabetic conditions. Pakistan Journal of Pharmaceutical

Sciences. 2004;17(1):25-30.

Jabbar J, Siddiqui I, Raza SQ, Baig A. To compare the total cholesterol and

HDL-cholesterol before and after ultra-centrifugation in lipemic samples. J

Pak Med Assoc. 2005 Jun;55(6):239-42.

Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of

hemodialysis on total antioxidant capacity and serum antioxidants in patients

with chronic renal failure. Clin Chem. 1995;41:1135-8.

Jacobs EM, Hendriks JC, van Tits BL, Evans PJ, Breuer W, Liu DY, et al.

Results of an international round robin for the quantification of serum non-

transferrin-bound iron: Need for defining standardization and a clinically

relevant isoform. Anal Biochem. 2005;341:241-50.

Jakeman A, Thompson T, McHattie J, Lehotay DC, Sensitive method for

nontransferrin-bound iron quantification by graphite furnace atomic

absorption spectrometry, Clinical Biochemistry. 2001;34(1):43-7.

REFERENCES

(212)

Jiang R, Ma J, Ascherio A, Stampfer MJ, Willett WC, Hu FB. Dietary iron

intake and blood donations in relation to risk of type 2 diabetes in men: a

prospective cohort study. Am J Clin Nutr. 2004;79:70-5.

Jittangprasert P, Wilairat P, Pootrakul P. Comparison of colorimetry and

electrothermal atomic absorption spectroscopy for the quantification of non-

transferrin bound iron in human sera. Southeast Asian J Trop Med Public

Health. 2004;35:1039-44.

Johonson AM, Rolfs EM, and Silverman LM ,(Proteins) In Tietz-Textbook of

Clinical Chemistry (Eds) Burtis A. B. and Ashwood E R (3rd

edition)

Philadelphia, 1999; (1) :482-90.

Joki N, Hase H, Ishikawa H, Fukazawa C, Nakamura R, Imamura Y, Tanaka

Y,Saijyo T, Fukazawa M, Yamaguchi T. Coronary artery disease as a

definitive risk factor of short-term outcome after starting hemodialysis in

diabetic renal failure patients. Clin Nephrol. 2001 Feb;55(2):109-14.

Judykay T. Nutrition for reducing urea and creatinine in the blood. Diabetes

Care. 2007;27:2191-2.

Kakhlon O, Cabantchik ZI. The labile iron pool: characterization,

measurement, and participation in cellular processes. Free Rad Biol Med.

2002;33:1037-46.

Kaplan A, Lavernel LS. Enzymes, In: Clinical Chemistry Interpretation and

Techniques, 2nd ed. Lea and Febiger, Philadelphia, (1983):173-217.

Kaplan LA. Carbohydrates and Metabolite, In: Clinical chemistry Theory,

analysis and correlation. Kaplan LA and Pesce AJ. Eds. CV. Mosby, Toronto,

1984:1032-40.

Kaplan LA, Pesce AJ. Hemoglobin porphyrin and iron metabolism, Clinical

chemistry and correlation. 1989;2:445-8.

Karnon J, Zeuner D, Brown J, Ades AE, Wonke B, Modell B. Lifetime

treatment costs of beta-thalassaemia major. Clin Lab Haematol. 1999

Dec;21(6):377-85.

Kartikasari AE, Georgiou NA, Visseren FL, van Kats-Renaud H, van Asbeck

BS, Marx JJ. Intracellular labile iron modulates adhesion of human monocytes

to human endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24:2257-62.

Knight JA. Free Radicals, Antioxidants, Aging and Disease. AACC Press,

1999, Washington, DC.

Knovich MA, Storey J, Coffman L, Torti S, Torti F. Ferritin for the clinician.

Blood Reviews. 2008;23(3):95-104.

REFERENCES

(213)

Knuiman MW, Divitini ML, Olynyk JK, Cullen DJ, Bartholomew HC. Serum

ferritin and cardiovascular disease: a 17- year follow-up study in Busselton,

Western Australia. Am J Epidemiol. 2003;158:144-9.

Kohgo Y, Ikuta K, Ohtake T, Torimoto Y, Kato J. Body iron metabolism and

pathophysiology of iron overload. Int J Hematol. 2008 Jul;88(1):7-15

Kolb AM, Smit NP, Lentz-Ljuboje R, Osanto S, van Pelt J. Non-transferrin

bound iron measurement is influenced by chelator concentration. Anal

Biochem. 2009;385:13-9.

Koo SW, Casper KA, Otto KB, Gira AK, Swerlick RA. Iron chelators inhibit

VCAM-1 expression in human dermal microvascular endothelial cells. J

Invest Dermatol. 2003;120:871-9.

Koorts AM, Viljoen M. Ferritin and ferritin isoforms I: structurefunction

relationships, synthesis, degradation and secretion. Arch Physiol Biochem.

2007;113:30-54.

Koppenol W.H. "The Haber-Weiss cycle - 70 years later". Redox Report.

2001;6:229-34.

Kosuge M, Kimura K, Ishikawa T, Ebina T, Hibi K, Tsukahara K, Kanna

M,Iwahashi N, Okuda J, Nozawa N, Ozaki H, Yano H, Nakati T, Kusama I,

Umemura S.Differences between men and women in terms of clinical features

of ST-segment elevation acute myocardial infarction. Circ J. 2006

Mar;70(3):222-6.

Kruszewski M. Labile iron pool: the main determinant of cellular response to

oxidative stress. Mutat Research. 2003;531:81-92.

Kruszewski M. The role of labile iron pool in cardiovascular diseases. Acta

Biochemical Polonica. 2004;51(2):471-80.

Kutty K, Mahender SK. Kochar's Concise Textbook of Medicine, 5th

ed,

Lippincott Williams and Wilkins,California;2003.

Le Lan C, Loréal O, Cohen T, Ropert M, Glickstein H, Lainé F, et al. Redox

active plasma iron in C282Y/C282Y hemochromatosis. Blood.

2005;105:4527-31.

Leake D, Rankin S. The oxidative modi. cation of low-density lipoproteins by

macrophages. Biochem J. 1990;270:741-8.

Lebowitz HE. Type 2 Diabetes: An Overview. Clin. Chem. 1999;45:1339-45.

REFERENCES

(214)

Lee DH, Folsom AR, Jacobs DRJ. Iron, zinc, and alcohol consumption and

mortality from cardiovascular diseases: the Iowa Women‟s Health Study. Am

J Clin Nutr. 2005;81:787-91.

Lee DH, Liu DY, Jacobs DR Jr, Shin HR, Song K, Lee IK, Kim B, Hider RC.

Common presence of non-transferrin-bound iron among patients with type 2

diabetes. Diabetes Care. 2006 May;29(5):1090-5.

Lele S, Shah S, McCullough PA, Rajapurkar M. Serum catalytic iron as a

novel biomarker of vascular injury in acute coronary syndromes.

EuroIntervention. 2009 Aug;5(3):336-42.

Leonardo AS, Cristiana C, Laura Z, Alessandra M, and Sergio D.

Abnormalities of Glucose Metabolism in Patients With Early Renal Failure. J

Diabetes. 2002;51:1226-36.

Lernmark A. Type 1 Diabetes. Clin. Chem. 1999;45(8Pt2):1331-38.

Levey AS , Bosch JP , Lewis JB , Greene T , Rogers N , Roth D, A more

accurate method to estimate GFR from serum creatinine: anew prediction

equation . Modification of Diet in Renal Disease Study Group. Ann intern

Med. 1999;130:461-71.

Lin JL, Lin Tan DT, Hsu KH, Yu CC. Environmental lead exposure and

progression of chronic renal diseases in patients without diabetes. N Engl J

Med. 2003;348:277-86.

Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline

in renal function with age. J Am Geriatr Soc. 1985;33: 278-85.

Liochev SI, Fridovich I. The relative importance of HO. and ONOO- in

mediating the toxicity of O•. Free Radic Biol Med. 1999;26:777-8.

Liu P, Olivieri N. Iron overload cardiomyopathies: new insights into an old

disease. Cardiovasc Drugs Ther. 1994;8:101-10.

Liuzzi JP, Aydemir F, Nam H, Knutson MD, Cousins RJ. Zip14 (Slc39a14)

mediates non-transferrin-bound iron uptake into cells Proc Natl Acad Sci

USA. 2006;103:13612-7.

Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of

human bone marrow. II. Normal B lymphocyte development. Blood.

1987;70:1316-24.

Longo-Mbenza B, Luila EL, Mbete P, Vita EK, Hyperuricemia a risk factor of

stroke and coronary heart disease among Africans. Int J Cardiol. 1999;71:17-

22.

REFERENCES

(215)

Loreal O, Gosriwatana I, Guyader D, Porter J, Brissot P, Hider RC.

Determination of non-transferrin-bound iron in genetic hemochromatosis

using a new HPLC-based method. J Hepatol. 2000;32:727-33.

Lovstad RA. Interaction of serum albumin with the Fe (III)-citrate complex.

Int J Biochem. 1993;25:1015-7.

Mahesh S, Ginzburg Y, Verma A. Iron overload in myelodysplastic

syndromes, Leuk Lymphoma. 2008;49:427-38.

Majumdar A and Wheeler DC, Lipid abnormalities in renal disease. J R Soc

Med. 2000;93:178-82.

Mallinson T. Myocardial Infarction. Focus on First Aid. 2010;15(15)

Retrieved 2010-06-08.

Marwah SS, Blann A, Harrison P, Lumley MA, Wright J, McDowell J,

Phillips JD,Rea C, Bareford D. Increased non-transferrin bound iron in

plasma-depleted SAG-M red blood cell units. Vox Sang. 2002 Apr;82(3):122-

6.

May PM, Williams DR, Computer simulation of chelation therapy. Plasma

mobilizing index as a replacement for effective stability constant. FEBS Lett.

1977;78:134-8.

McKie AT, Latunde-Dada GO, Miret S, et al. Molecular evidence for the role

of a ferric reductase in iron transport. Biochem Soc Trans. 2002;30:722-4.

Mendler MH, Turlin B, Moirand R, Jouanolle AM, Sapey T, Guyader D, et al.

Insulin resistance-associated hepatic iron overload. Gastroenterology.

1999;117:1155-63.

Meyers DG. The iron hypothesis: does iron play a role in atherosclerosis?

Transfusion. 2000;40:1023-9.

Michael JF. Role of sodium in hemodialysis. Kidney International USA.

2000;58,Suppl.76,72-8

Mingwei Q, Michael L, John WE. Transition Metals Bind to Glycated protein

forming redox active “Glycochelates”: Implications for the pathogenesis of

certain Diabetic complications. Biochemical and Biophysical research

communication. 1998;250:385-9.

Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the

UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051-2.

Mohan S, Kalia K, Mannari J. Diabetic nephropathy and associated risk

factors for renal deterioration. Int J diabetes Dev Ctries. 2011;32:52-9.

REFERENCES

(216)

Moss DW, Henderson AK, Clinical enzymology, In Tietz textbook of clinical

chemistry. 3rd

edition, Burtis CA and Ashwood ER, Eds .WB Saunders,

Philadelphia. 1999;617-721.

Muhlestein JB. Cardiac abnormalities in hemochromatosis. In: Barton JC,

Edwards CQ, eds. Hemochromatosis: genetics, pathophysiology, diagnosis,

and treatment. Barton JC, Edwards CQ, eds. Cambridge: Cambridge

University Press; 2000;297-310.

Muncie HL Jr, Campbell J. Alpha and beta thalassemia. Am Fam Physician.

2009 Aug 15;80(4):339-44. Review.

Murry RL. Non Protein Nitrogenous Compounds, In: Cilinical chemistry

theory, Analysis and correlation. Kaplan LA and Pesce AJ. Eds. CV. Mosby,

Toronto, (1984): 1230-68.

Nankivell BJ, Boadle RA, Harris DCH. Iron accumulation in human chronic

renal disease. Am J Kidney Dis. 1992;20:580-4.

Newman and Price CP. Renal function and nitrogen metabolites, In: Tietz

textbook of clinical chemistry. 3rd

edition, Burtis CA and Ashwood ER, Eds.

WB Saunders, Philadelphia. 1991;1204-64.

Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer

G. Long-term survival in patients with hereditary hemochromatosis.

Gastroenterology 1996;110:1107-19

Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ,

Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic

patients with primary hemochromatosis. N Engl J Med 1985;313:1256-62.

Nilsson UA, Bassen M, Sävman K, Kjellmer I. A simple and rapid method for

the determination of "free" iron in biological fluids. Free Radic Res.

2002;36:677-84.

Nolan CR, Anderson RJ, Hospital-acquired acute renal failure. Jam Soc

Nephrol. 1998;9:710-8.

Old JM, Olivieri NF, Thein SL. Diagnosis and management of thalassaemia.

In: Weatherall DJ, Clegg B, eds. The thalassaemia syndromes.4th ed. Oxford,

England: Blackwell Science, 2001:630-85.

Olivieri NF, Brittenham GM, Iron chelation therapy and treatment of

thalassemia. Blood. 1997;89:739-61.

Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated

patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-8.

REFERENCES

(217)

Olivieri NF. The beta-thalassemias. N Engl J Med 1999;341:99-109.

Ostlund RE, Racette, SB, and Stenson WF, "Inhibition of Cholesterol

absorption by phytosterols-replete wheat germ Compared with phytosterols-

depleted wheat germ". Am J Clin Nutr. 2003;77(6):1385-6.

Oudit GY, Trivieri MG, Khaper N, Husain T, Wilson GJ, Liu P, et al. Taurine

supplementation reduces oxidative stress and improves cardiovascular

function in an iron-overload murine model. Circulation. 2004;109:1877-85.

Paffetti P, Perrone S, Longini M, Ferrari A, Tanganelli D, Marzocchi B, et al.

Non-protein-bound iron detection in small samples of biological fluids and

tissues. Biol Trace Elem Res. 2006;112:221-32.

Pagana and Pagana. Moshby‟s manual of diagnostic and laboratory tests. 3rd

ed. Moshby Elsevier, USA, 2006.

Pai B, Pai MP, Depczynski J, McQuade CR, Mercier RC. Nontransferrin-

bound iron is associated with enhanced Staphylococcus aureus growth in

hemodialysis patients receiving intravenous iron sucrose. Am. J. Nephrol.

2006;26:304-9.

Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl

Pharmacol. 2005 Jan 15;202(2):199-211. Review.

Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial

peptide synthesized in the liver. J Biol Chem. 2001;276:7806-10.

Pietrangelo A. Hemochromatosis: an endocrine liver disease. Hepatology.

2007;46:1291-301.

Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and

treatment. Gastroenterology. 2010 Aug;139(2):393-408.

Pietrangelo A. Hereditary hemochromatosis—a new look at an old disease. N

Engl J Med. 2004;350:2383-97.

Ponka P. Tissue-specific regulation of iron metabolism and heme synthesis:

distinct control mechanisms in erythroid cells. Blood. 1997;89:1-25.

Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C,

Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma

redox activity in iron-overloaded b-thalassemia/HbE patients treated with an

oral chelator. Blood. 2004;104:1504-10.

Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Maungsub W, Sriphen

K, et al. Clinical trial of deferiprone iron chelation therapy in beta-

REFERENCES

(218)

thalassaemia/haemoglobin E patients in Thailand. Br J Haematol.

2003;122:305-10.

Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of

removal and reappearance of nontransferrin- bound plasma iron with

deferoxamine therapy. Blood. 1996;88:705-13.

Porter JB. Pathophysiology of transfusional iron overload: Contrasting

patterns in thalassemia major and sickle cell disease Hemoglobin

2009;33:S37- S45.

Prabhu R, Prabhu V, Prabhu RS. Iron over load in beta thalassemia. J Biosci

Tech. 2009;1(1):20-31.

Prakash M, Upadhya S, Prabhu R. Serum non-transferrin bound iron in

hemodialysis patients not receiving intravenous iron. Clin Chim Acta. 2005

Oct;360(1-2):194-8.

Praticó D, Pasin M, Barry OP, Ghiselli A, Sabatino G, Iuliano L,et al. Iron-

dependent human platelet activation and hydroxyl radical formation:

involvement of protein kinase C. Circulation. 1999;99:3118-24.

Prus E, Fibach E. Uptake of non-transferrin iron by erythroid cells. Anemia.

2011;Article ID 945289, 8 pages.

Puppo A, Halliwell B. Formation of hydroxyl radicals from hydrogen peroxide

in the presence of iron: is haemoglobin a biological Fenton catalyst? Biochem

J. 1988;249:185-90.

Qian M, Liu M, Eaton JW. Transition Metals Bind to Glycated Proteins

Forming Redox Active “Glycochelates”: Implications for the Pathogenesis of

Certain Diabetic Complications. Biochemical and biophysical research

communications. 1998;250:385-89.

Ramakrishnan U, Kuklina E, Stein AD: Iron stores and cardiovascular disease

risk factors in women of reproductive age in the United States. Am J Clin

Nutr. 2002;76:1256-60.

Redmon JB, Pyzdrowski KL, Robertson RP. No effect of deferoxamine

therapy on glucose homeostasis and insulin secretion in individuals with

NIDDM and elevated serum ferritin. Diabetes. 1993;42:544-9.

Richardson DR, Ponka P. The molecular mechanisms of the metabolism

andtransport of iron in normal and neoplastic cells. Biochim Biophys Acta.

1997 Mar 14;1331(1):1-40.

Robert W. Schrier, Manual of Nephrology. Medical. 2004:350-52.

REFERENCES

(219)

Roche M, Rondeau P, Singh N, Tarnus E, Bourdon E. The antioxidant

properties of serum albumin. Federation of European Biochemical Societies

Letters. 2008;582:1783-7.

Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L. The role of

oxidative stress in the onset and progression of diabetes and its complications:

a summary of a Congress Series sponsored by UNESCO-MCBN, the

American Diabetes Association and the German Diabetes Society. Diabetes

Metab Res Rev. 2001May-Jun;17(3):189-212.

Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med.

1999;340:115-26.

Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on

creatinine clearance in men: a cross-sectional and longitudinal study. J

Gerontol. 1976;31:155-63.

Roy CN, Enns CA. Iron homeostasis: new tales from the crypt. Blood.

2000;96:4020-7.

Rund D and Rachmilewitz E. β-Thalassemia. N Engl J Med. 2005;353:1135-7.

Ryter SW, Tyrrell RM. The heme synthesis and degradation pathways: role in

oxidant sensitivity. Heme oxygenase has both pro- and antioxidant properties.

Free Radical Biol. Med. 2000;28:289-309.

Sahlstedt L, Ebeling F, von Bonsdorff L, Parkkinen J, Ruutu T. Non-

transferrin-bound iron during allogeneic stem cell transplantation. Br J

Haematol. 2001;113:836-8.

Sahlstedt L, Von Bonsdorff L, Ebeling F, Parkkinen J, Juvonen E and Ruutu

T. Non-transferrin-bound iron in haematological patients during chemotherapy

and conditioning for autologous stem cell transplantation. European Journal of

Haematology. 2009;83:455-9. doi: 10.1111/j.1600-0609.2009.01310.x.

Salvemini D, Wang ZQ, Bourdon DM, Stern MK, Currie MG, Manning PT.

Evidence of peroxynitrite involvement in the carrageenan-induced rat paw

edema. Eur J Pharmacol. 1996;303:217-20.

Sargent PJ, Farnaud S, Evans RW. Structure/function overview of proteins

involved in iron storage and transport. Curr Med Chem. 2005;12:2683-93.

Sasaki K, Ikuta K, Tanaka H, Ohtake T, Torimoto Y, Fujiya M, et al.

Improved quantification for non-transferrin-bound iron measurement using

high-performance liquid chromatography by reducing iron contamination. Mol

Med Report. 2011;4:913-8.

REFERENCES

(220)

Satyanarayana U and Chakrapani U. Biochemistry. 3rd

ed. Uppala author-

publisher interlink, Vijaywada, 2009.

Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, et al.

Clinical consequences of acquired transfusional iron overload in adults. N

Engl J Med. 1981;304:319-24.

Schaller Georg, Barbara Scheiber-Mojdehkar, Michaelwolzt, Heidi puttinger,

Friedrich mittermayer, Intravenous iron increases labile serum iron but does

not impair forearm blood flow reactivity in dialysis patients November,

Kidney Int. 2005;68:2814-22.

Schellhammer PF, Engle MA, Hagstrom JW. Histochemical studies of the

myocardium and conduction system in acquired iron-storage disease.

Circulation. 1967;35:631-7.

Schumann G, IFCC Primary reference procedures for the measurement of

catalytic activity of enzymes at 37˚C. J Clin Chem Lab med. 2002; 40:725-

733.

Sempos CT, Looker AC, Gillum RE, Mc- Gee DL, Vuong CV, Johnson CL.

Serum ferritin and death from all causes and cardiovascular disease: the

NHANES II Mortality Study. Ann Epidemiol. 2000;10:441-8.

Shah SV, Baliga R, Rajapurkar M, Fonseca VA. Oxidants in chronic kidney

disease. J Am Soc Nephrol. 2007;18:16-28.

Shah SV. Oxidants and iron in chronic kidney disease. Kidney Int Suppl.

2004;91:50-5.

Sharma M, Gohil NK. Interaction of azotobactin with blocking and mobilizing

agents in NTBI assay. Mol Biosyst. 2010;6:1941-6.

Sharma M, Saxena R, Gohil NK. Fluorescence assay of non-transferrin-bound

iron in thalassemic sera using bacterial siderophore. Anal Biochem.

2009;394:186-91.

Shetty JK, Prakash M, Ibrahim MS. Relationship between free Iron and

glycated hemoglobin in uncontrolled type 2 diabetes patients associated with

complications. Indian J Clin Biochem. 2008;23(1):67-70.

Shoback, edited by David G. Gardner, Dolores. Greenspan's basic & clinical

endocrinology. 9th

ed. New York: McGraw-Hill Medical; 2011. Chapter

17. ISBN 0-07-162243-8.

Silva AM, Hider RC. Influence of non-enzymatic post-translation

modifications on the ability of human serum albumin to bind iron implications

REFERENCES

(221)

for non-transferrin- bound iron speciation. Biochim Biophys

Acta.2009;1794:1449-58.

Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a

review. Diabetologia. 2001;44:129-46.

Singh S, Hider RC, Porter JB. A direct method for quantification of non-

transferin-bound iron. Anal Biochem. 1990;186:320-3.

Skutches C, Holroyde C, Myers R. et al. Plasma acetate turnover and

oxidation. J Clin Invest. 1979;64(3):708-13.

Smith LL. Another cholesterol hypothesis: cholesterol as antioxidant. Free

Radical. Biol Med. 1991;11(1):47-61.

Smith HW. The Kidney: Structure and Function in Health and Disease, p. 57.

Oxford University Press, New York; 1951.

Steptoe A, Kivimäki M. Stress and cardiovascular disease. Nat Rev Cardiol.

2012 Apr 3;9(6):360-70. doi: 10.1038/nrcardio.2012.45. Review.

Stewart, W.B., Yuile, C.L., Claiborne, H.A., Snowman, R.T., Whipple, G.H.

Radioiron absorption in anemic dogs; fluctuations in the mucosal block and

evidence for a gradient of absorption in the gastrointestinal tract. J. Exp. Med.

1950;92,375- 82.

Stuart KA, Anderson GJ, Frazer DM, et al. Duodenal expression of iron

transport molecules in untreated haemochromatosis subjects. Gut.

2003;52(7):953-9.

Sulieman M, Asleh R, Cabantchik ZI, Breuer W, Aronson D, Suleiman A,

Miller-Lotan R, Hammerman H, Levy AP. Serum chelatable redox-active iron

is an independent predictor of mortality after myocardial infarction in

individuals with diabetes. Diabetes Care. 2004 Nov;27(11):2730-2.

Sullivan JL: Iron and the sex difference in heart disease risk. Lancet.

1981;1:1293-4.

Suryawanshi NP, Bhutey AK, Nagdeote AN, Jadhav AA and Manoorkar GS.

Study of Lipid peroxide and Lipid profile in Diabetes Mellitus. Indian J Clin

Biochem. 2006;21(1):126-30.

Takahashi S, Warabayasi Y, Nakai T, Sakai J and Yamamoto T, Rabbit very

low density lipoprotein receptor: a low density lipoprotein receptor-like

protein with distinct ligand specificity. Proc Natl Acad Sci USA. 1992;89:

9252-6.

Telfer P, Coen PG, Christou S, Hadjigavriel M, Kolnakou A, Pangalou E,

Pavlides N, Psiloines M, Simamonian K, Skordos G, Sitarou M,Angastiniotis

REFERENCES

(222)

M: Survival of medically treated thalassemia patients in Cyprus. Trends and

risk factors over the period 1980-2004. Haematologica. 2006;91:1187-92.

Termini J. Hydroperoxide-induced DNA damage and mutations. Mutat Res.

2000;450:107-24.

Terres W, Beil U, Riemann B, and Tiede S, Bleifeld W, Low dose fish oil in

primary hypertriglyceridemia. A randomized placebo-controlled study in

German. Festschrift für Cardiologic. 1991;80(1):20-4.

Tietz Text book of clinical chemistry. Lipid, Lipoprotein and Apolipoproteins.

3rd

ed. Burtis CA and Ashwood ER, Eds .WB Saunders, Philadelphia; 1999.

Tietz N.W. Fundamentals of Clinical Chemistry. 5th

ed, Philadelphia,

W.B.Saunders; 1976.

Teitz Text book of Clinical Chemistry and Molecular Diagnostics, 4th

edition

Elsevier Saunders, St. Louis, Missouri ; 2006.

Trinder D, Fox C, Vautier G, Olynyk JK. Molecular pathogenesis of iron

overload. Gut. 2002;51:290-5.

Tsaltas TT and Friedman EA. Plasma lipid studies in uremic patients during

hemodialysis. Amer. J Clin Nutr.1968;21:430-5.

Turk HM, Sevinc A, Camci C, Cigli A, Buyukberber S, Savli H, Bayraktar N.

Plasma lipid peroxidation products and antioxidant enzyme activities in

patients with type 2 diabetes mellitus. Acta Diabetol. 2002 Sep;39(3):117-22.

Valensi P, Lorgis L, Cottin Y. Prevalence, incidence, predictive factors and

prognosis of silent myocardial infarction: a review of the literature. Arch

Cardiovasc Dis. 2011 Mar;104(3):178-88.

van der ADL, Marx JJ, Grobbee DE, Kamphuis MH, Georgiou NA, van Kats-

Renaud JH, Breuer W, Cabantchik ZI, Roest M, Voorbij HA, van der Schouw

YT. Non-transferrin-bound iron and risk of coronary heart disease in

postmenopausal women. Circulation. 2006 Apr 25;113(16):1942-9. Epub 2006

Apr 17. Erratum in: Circulation. 2006 May 30;113(21):e784.

van der ADL, Peeters PH, Grobbee DE, Marx JJ, van der Schouw YT. Dietary

haem iron and coronary heart disease in women. Eur Heart J. 2005;26:257-62.

van der Heul C, van Eijk HG, Wiltink WF, Leijnse B. The binding of iron to

transferrin and to other serum components at different degrees of saturation

with iron, Clin Chim Acta. 1972;38:347-53.

Van Wyck DB. Labile iron: manifestations and clinical implications. J Am

Soc Nephrol. 2004 Dec;15 Suppl2:S107-11.

REFERENCES

(223)

Vasudevan DM, Sreekumari S, Kannan Vaidyanathan. Mineral Metabolism

and Abnormalities. Text book of biochemistry for Medical students, 6th

ed.

Jaypee Brothers Medical Publishers (P) Ltd. New Delhi; 2011.

Vasudevan DM, Sreekumari S. Text book of Biochemistry for Medical

students. 3th

ed. Jaypee Brothers Medical Publishers (P) Ltd. New Delhi; 2001.

Victoria SL and Joel DK, Protein metabolism in patients with chronic renal

failure: Role of uraemia and dialysis Division of Nephrology, Department of

Medicine, University of Iowa College of Medicine, Torrance, and the UCLA

Schools of Medicine and Public Health, Los Angeles, California. USA,

Kidney International. 2000;58:1-10.

Vincent CJ. Laboratory tests and diagnostic procedures. 5th

ed. Julie

Alexander, New Jersey; 2000.

von Bonsdorff L, Lindeberg E, Sahlstedt L, Lehto J, Parkkinen J. Bleomycin-

detectable iron assay for non-transferrin-bound iron in hematologic

malignancies. Clin Chem. 2002;48:307-14.

Voogd A, Sluiter W, Koster JF. The increased susceptibility to hydrogen

peroxide of the (post-) ischemic rat heart is associated with the magnitude of

the low molecular weight iron pool. Free Radic Biol Med. 1994;16:453-8.

Walter GO. Iron deficiency anemia. Lecture in hematology,1974:493-502.

Washington DC. Living with kidney disease: a patient manual fifth edition.

September, 2002;13-15.

Washington DC. Living kidney failure. Superintendent of Documents

Government Printing Office 20402; (2002):783-3238.

Weatherall DJ, Clegg JB: The thalassaemia syndromes 4th

edition. Oxford,

England: Blackwell Science; 2001.

Weijl NI, Elsendoorn TJ, Moison RM, Lentjes EG, Brand R, Berger HM,

Osanto S. Non-protein bound iron release during chemotherapy in cancer

patients. Clin Sci(Lond). 2004 May;106(5):475-84.

West IC. Radicals and Oxidative stress in Diabetes. Diabet. Med.

2000;17:171-80.

William j Marshall, Clinical biochemistry (Acute renal failure in critically ill

patients: A multinational, multicenter study. Article \Pub med \ISI \chemport.

JAMA (2004); 204:813-18.

Williams textbook of endocrinology, 12th

ed. Philadelphia: Elsevier/Saunders;

2011. ISBN 978-1-4377-0324-5.

REFERENCES

(224)

World Health Organization (2008). The Global Burden of Disease: 2004

Update. Geneva: World Health Organization. ISBN 92-4-156371-0

Yen AW, Fancher TL, Bowlus CL. Revisiting hereditary hemochromatosis:

current concepts and progress. Am J Med. 2006;119:391-9.

Zhang D, Okada S, Kawabata T, Yasuda T. An improved simple colorimetric

method for quantification of non-transferrin-bound iron in serum. Biochem

Mol Biol Int. 1995;35:635-41.

Zhang WJ, Frei B. Intracellular metal ion chelators inhibit TNF alpha-induced

SP-1 activation and adhesion molecule expression in human aortic endothelial

cells. Free Radic Biol Med. 2003;34:674-82.